Clinical Outcomes of Patients With NSCLC With Uncommon EGFR Mutations Treated With Afatinib vs Osimertinib
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Oncologist
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis
Oncologist 2023 Apr 28;[EPub Ahead of Print], C Wang, K Zhao, S Hu, W Dong, Y Gong, C XieFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.